Key Points
- Director William Carson purchased 8,000 Annexon shares at an average price of $5.67 on March 10 (SEC Form 4), increasing his ownership to 62,405 shares — a 14.70% rise in his stake.
- ANNX traded up about 4.5% to $5.69 with a market cap near $680M and a 52-week range of $1.28–$7.18; analysts have a consensus "Moderate Buy" with an average price target of $17, while Wells Fargo notably raised its target to $27.
Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William Carson bought 8,000 shares of the stock in a transaction on Tuesday, March 10th. The stock was purchased at an average price of $5.67 per share, with a total value of $45,360.00. Following the completion of the purchase, the director owned 62,405 shares of the company's stock, valued at $353,836.35. This represents a 14.70% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
Annexon Trading Up 4.5%
Shares of ANNX stock traded up $0.25 during trading hours on Friday, reaching $5.69. 1,055,317 shares of the company's stock were exchanged, compared to its average volume of 2,524,902. The stock's 50 day moving average is $5.70 and its 200-day moving average is $4.24. The company has a market cap of $680.10 million, a price-to-earnings ratio of -4.02 and a beta of 1.15. Annexon, Inc. has a fifty-two week low of $1.28 and a fifty-two week high of $7.18.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on ANNX. Wells Fargo & Company upped their target price on Annexon from $14.00 to $27.00 and gave the company an "overweight" rating in a research report on Wednesday, November 19th. Cantor Fitzgerald restated an "overweight" rating on shares of Annexon in a research note on Wednesday, January 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Annexon in a report on Wednesday, January 21st. Finally, Chardan Capital assumed coverage on shares of Annexon in a research note on Tuesday, December 23rd. They issued a "buy" rating and a $16.00 target price for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $17.00.
View Our Latest Report on ANNX
Institutional Investors Weigh In On Annexon
A number of institutional investors and hedge funds have recently modified their holdings of the company. CIBC Bancorp USA Inc. acquired a new stake in Annexon during the third quarter valued at $31,000. Engineers Gate Manager LP purchased a new stake in shares of Annexon during the 2nd quarter worth about $32,000. SG Americas Securities LLC acquired a new stake in shares of Annexon during the 3rd quarter valued at about $34,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company's stock valued at $35,000 after purchasing an additional 2,785 shares in the last quarter. Finally, Savant Capital LLC acquired a new position in Annexon in the 3rd quarter worth about $40,000.
About Annexon
(
Get Free Report)
Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.
At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
